Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression

Ip, Michael S.

doi:10.1001/archophthalmol.2012.1043

Cited by 229 publications

(182 citation statements)

References 20 publications

Supporting

Mentioning

168

Contrasting

Unclassified

Order By: Relevance

“…FDA approved ranibizumab for the treatment of DME in 2012 and for the treatment of DR in February 2015. Evidence for DME treatment with ranibizumab is based on data from phase II and III RTCs, including the Safety and Effi cacy of Ranibizumab in DME (RESOLVE) 55 ; Ranibizumab for Edema of the mAcula in Diabetes (READ-2) 56 ; Core Study to Assess the Effi cacy and Safety of Ranibizumab Intravitreal Injections (RESTORE) 57 ; Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol I 58 and Study of Ranibizumab Injection in Subjects with CS-DME Secondary to Diabetes (RISE and RIDE) 59 . Afl ibercept (Eylea®; Bayer Healthcare Pharmaceuticals, Berlin, Germany) is a 115-kDA recombinant fusion protein consisting of the VEGF binding domains of human VEGF receptors 1 and 2 fused to the Fc domain of human immunoglobulin-G1 60 .…”

Section: Novel Treatment Options For Dmementioning

confidence: 99%

Diabetic Macular Edema: Traditional and Novel Treatment

Tomić

Poljičanin³

et al. 2017

acc

View full text Add to dashboard Cite

SUMMARY -Diabetes is one of the leading public health problems worldwide. Diabetic macular edema (DME) is the main cause of vision loss in patients with diabetes. Ideal metabolic control of diabetes is the primary goal of treatment and the basic way of preventing and stopping the progression of DME. Although laser photocoagulation has been the standard treatment of DME for nearly three decades, superior outcomes can be achieved with novel, intravitreal anti-VEGF and steroid therapy. Novel treatment option for DME depends on visual acuity and location/extent of macular thickening based on optical coherence tomography scans. According to the International Clinical Classifi cation Scale, DME is divided into no center-involving DME and center-involving DME (CI-DME). New guidelines recommend intravitreal treatment as the treatment of choice for patients with CI-DME and moderate visual impairment. Patients with no CI-DME and mild visual impairment should be treated with modifi ed ETDRS laser photocoagulation and closely observed. Vitrectomy is the treatment of choice for patients with a tractional component of DME. Nowadays, traditional treatment goal of preventing blindness in patients with DME has been changed by the new goal aiming to restore impaired vision, prevent further vision loss and improve visual function. Th erefore, many trials addressing this new concept have been underway worldwide.

show abstract

Section: Novel Treatment Options For Dmementioning

confidence: 99%

Diabetic Macular Edema: Traditional and Novel Treatment

Tomić

Poljičanin³

et al. 2017

acc

View full text Add to dashboard Cite

show abstract

“…These studies showed that high levels of VEGF cause closure of retinal vessels, which for a period of time can be reopened by VEGF suppression, but, without treatment or by suspending treatment, permanent closure and retinal nonperfusion occur. Suppression of VEGF also resulted in improvements in background diabetic retinopathy (36). Thus, VEGF plays a larger role in the pathogenesis of ischemic retinopathies than previously expected, but the mechanism by which it promotes reversible vessel closure is unknown.…”

Section: Introductionmentioning

confidence: 85%

Reversible retinal vessel closure from VEGF-induced leukocyte plugging

Liu¹,

Shen²,

Fortmann³

et al. 2017

JCI Insight

View full text Add to dashboard Cite

“…For example, the Diabetic Retinopathy Clinical Research Network (DRCRnet) suggests that the average number of injections in the first, second, and third year of treatment for DME was 9, 3, and 2, respectively, to maintain vision gained (17). Exploratory analysis of trial data demonstrated that ranibizumab injections could reduce risk of progression and increase likelihood of regression of diabetic retinopathy severity among patients with DME (19).…”

Section: Efficacymentioning

confidence: 99%

Ocular Anti-VEGF Therapy for Diabetic Retinopathy: Overview of Clinical Efficacy and Evolving Applications

2014

View full text Add to dashboard Cite

Ocular anti-vascular endothelial growth factor (VEGF) therapy represents one of the most significant advances in modern medicine. The introduction and widespread use of ocular anti-VEGF therapy for age-related macular degeneration heralded a new era in the treatment of vascular and exudative diseases of the retina. Its expanding indications now include diabetic macular edema and proliferative diabetic retinopathy, two vision-threatening forms of diabetic retinopathy. It is widely anticipated that ocular anti-VEGF therapy could spark a dramatic shift in the treatment paradigm for diabetic retinopathy. However, despite its clear efficacy shown in clinical trials, the dynamic landscape of evolving medical, ethical, and economic issues related to this new treatment suggests significant challenges ahead. In this article, we provide a discussion of this topic as part of this two-part Bench to Clinic narrative. Here, our Clinic contribution provides an overview of the current evidence from clinical trials on anti-VEGF therapy for diabetic retinopathy, and highlights the hopes and fears of this new treatment from clinical and public health standpoints. In the Bench narrative that precedes this contribution, Simó et al. provide an overview of the role of VEGF in the pathogenesis of diabetic retinopathy.

show abstract

Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression

Cited by 229 publications

References 20 publications

Diabetic Macular Edema: Traditional and Novel Treatment

Diabetic Macular Edema: Traditional and Novel Treatment

Reversible retinal vessel closure from VEGF-induced leukocyte plugging

Ocular Anti-VEGF Therapy for Diabetic Retinopathy: Overview of Clinical Efficacy and Evolving Applications

Contact Info

Product

Resources

About